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Aims To estimate the cost-effectiveness of 10 mg rosuvastatin daily for older patients with systolic heart failure in the Con-
trolled Rosuvastatin Multinational Study in Heart Failure (CORONA) trial.
Methods
and results
This within trial analysis of CORONA used major cardiovascular (CV) events as the outcome measure. Resource use
was valued and the costs of hospitalizations, procedures, and statin use compared. Cost-effectiveness was estimated
as cost per major CV event avoided. There were signiﬁcantly fewer major CV events in the rosuvastatin group com-
pared with the placebo group (1.04 vs. 1.20 per patient; difference 0.164; 95% CI: 0.075–0.254, P , 0.001). The
average cost of CV hospitalizations and procedures was signiﬁcantly lower for those receiving rosuvastatin (£1531
vs. £1769; difference £238; 95% CI: £73–403, P ¼ 0.005); the additional cost of the statin resulted in signiﬁcantly
higher total costs for the rosuvastatin group (£1769 vs. £2072; difference £303; 95% CI: £138–468, P , 0.001).
Overall, rosuvastatin was found to cost £1840 (95% CI: £562–6028) per major CV event avoided.
Conclusion This economic analysis showed that a signiﬁcant reduction in major CV events with rosuvastatin led to signiﬁcantly
reduced costs of CV hospitalizations and procedures. The reduction in associated costs for major CV events was
found to offset partially (by 44%) the cost of rosuvastatin treatment in patients with systolic heart failure.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Heart failure is a major public health problem. Incidence, preva-
lence, and risk have been found to be high in both Europe and
the United States.
1,2 The Rotterdam study
1 found that a male
(female) aged 55 years old has 33.0% (28.5%) chance of developing
heart failure during their remaining lifetime; while the Framingham
Heart Study
2 reported a lifetime risk at age 50 of 20.9% for men
and 20.5% for women. The Rotterdam study further showed
that the prevalence of heart failure increased with time and age;
in 1998, 0.9% of subjects aged 55–64 had heart failure, compared
with 17.4% of those aged 85 years or over. The combination of an
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has the greatest incidence of heart disease, and improved survival
after acute myocardial infarction (MI) is, therefore, likely to further
increase the prevalence of heart failure.
3
This increasing clinical burden is expected to be matched with an
increasing ﬁnancial burden. Using a prevalence-based approach the
economic burden of heart failure in the UK was estimated to be
£905.3 million in 2000, a 26% increase on 1995 estimates, and equiv-
alent to 1.91% of total NHS expenditure.
4 The major contributor to
this ﬁnancial burden is hospitalization, as such there is potential to
reduce the burden if admissions to hospital and durations of hospital
stay can be reduced. Indeed, it has been estimated that reducing
length of stay by 1 day or reducing re-admissions by 50% could gen-
erate annual cost savings of between £50 and £120 million.
4
HMG-CoA reductase inhibitors or ‘statins’ have been found to
be beneﬁcial in people with or at risk of cardiovascular (CV)
disease, and importantly they have also been shown to be cost
effective.
5 However, existing statin trials generally excluded
patients with heart failure leading to uncertainty about their poten-
tial role in that condition.
6
The Controlled Rosuvastatin Multinational Study in Heart
Failure (CORONA) trial was the ﬁrst large-scale, prospective, ran-
domized, placebo-controlled study to determine the effect of
statins on clinical outcomes in patients with heart failure.
7,8 This
paper estimates the cost-effectiveness of a daily dose of 10 mg
of rosuvastatin during the study treatment period.
Methods
Clinical trial
The CORONA trial assessed the effects of rosuvastatin on mortality
and morbidity in patients with chronic systolic heart failure. Patients
were allocated in a ratio of 1:1 to 10 mg rosuvastatin or matching
placebo. Patients were recruited at 378 centres in 21 countries. The
trial was approved by the Ethics Committee at each of the participating
hospitals, and patients provided written informed consent. An econ-
omic analysis plan was drafted in advance of the data being released.
The plan was developed using a slice of treatment-blinded trial data.
Details of the trial have been reported elsewhere,
7 but in short
patients aged 60 years or older with chronic symptomatic (NYHA
functional class II–IV) heart failure of ischaemic aetiology and with
an ejection fraction of  0.40 ( 0.35 if NYHA class II) were included.
Patients already on a statin (or other lipid lowering drug) or considered
by their own doctor to need (or have a contraindication to) a statin
were not randomized. Lipid lowering treatment could not be
stopped to make a patient eligible for inclusion. Furthermore, patients
who had been treated with a statin previously were not eligible for ran-
domization until 6 months after withdrawal of the statin.
The primary trial outcome was the composite of CV mortality, non-
fatal MI, or non-fatal stroke, analysed as time to the ﬁrst event. The
secondary outcomes were all-cause mortality, any coronary event,
CV mortality, and number of hospitalizations (for CV causes, unstable
angina, and worsening heart failure).
Endpoint classiﬁcation
All serious adverse events were classiﬁed by an independent Endpoint
Committee (Appendix 1), such that no pre-selection exclusion of
potential clinical events was undertaken by the investigators at a site
level. In contrast to most previous trials, the adjudication comprised
all possible non-CV and CV events. The Endpoint Committee used
all available information such as relevant case report forms, reports
of serious adverse events, copies of hospital discharge summaries,
ECGs, and enzymes (if an acute MI was suspected or reported), phys-
icians’ records, discharge letters, police reports, death certiﬁcates, and
autopsy reports, blinded to subject identiﬁers. For each hospitalization
one main reason was given for admission according to a pre-speciﬁed
Endpoint Classiﬁcation Manual. If a pre-speciﬁed complication (a new MI,
new stroke, or unstable angina) occurred during the hospitalization,
and was not the reason for admission, these were also adjudicated
and recorded, as were pre-speciﬁed procedures (percutaneous trans-
luminal coronary intervention (PCI), coronary artery bypass graft
(CABG), and cardiac transplant). In addition if a non-fatal stroke
occurred outside hospital this was also adjudicated and recorded.
Hospitalization was deﬁned as care at an acute care hospital lasting
 24 h. Cardiovascular causes were classiﬁed as cardiac causes (aggra-
vated heart failure, acute MI, unstable angina, or other cardiac with
diagnosis in full text) or non-cardiac (ischaemic, haemorrhagic or
unclassiﬁable stroke, or other non-cardiac with diagnosis in full text).
Non-CV causes were given in full text by the Endpoint Committee.
Hospitalization for heart failure required documentation that worsen-
ing heart failure was the principal reason for hospitalization and, if com-
peting reasons were judged to be of equal importance, heart failure
was given preference. Deaths were classiﬁed in a similar way.
Health outcomes
Since the total number of major CV events was of greater interest than
the primary endpoint (patient-based time to ﬁrst event) from an econ-
omic perspective, the outcome used in the cost-effectiveness analysis
was the total number of combined major fatal and non-fatal CV events
avoided (as opposed to patients having events). ‘Major CV events’
were deﬁned as any of the endpoints described earlier, that is: CV hos-
pitalizations, additional CV events occurring while in hospital, CV
events not requiring hospitalisation, and CV deaths. These events
were aggregated for each individual (taking care to avoid double count-
ing) and the total and mean number of events per patient were com-
pared between the treatment and placebo groups.
Resource use and cost
The cost of health care comprises resource use counts and the unit cost
of these resources. A range of resource use components were routinely
collected during the trial. These include hospitalizations (the nature of
the hospitalization and the length of stay), procedures, and medications.
Primary care costs, over-the-counter medications, and patient costs
were not collected. The perspective employed in the economic evalu-
ation was that of the health care sector, i.e. direct costs to the patient
and potential productivity costs to society were not estimated.
The index country for the cost analysis was the UK; all costs used
2005/06 as the base year (no inﬂationary adjustment was required).
NHS Reference Costs
9 were employed to value all hospitalizations
and procedures, and while the costs of the more speciﬁc hospitaliz-
ations (MI, stroke, heart failure, and unstable angina) were easily ident-
iﬁed, there were numerous (and many rare) CV and non-CV
hospitalizations which required valuation. In order to cost accurately
these events, two members of the Independent Endpoint Committee
assigned ICD-10 codes to all CV and non-CV hospitalizations (OPCS-4
codes were used when hospitalizations explicitly involved procedures).
These codes were then mapped to HRG (Healthcare Resource
Group) codes using HRG4 Reference Cost Grouper software
10
which were subsequently assigned a cost from the National Schedule
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9 Appendix 2 presents an example
of the main unit costs that were employed in the analysis, the National
Schedule (non-elective inpatient stay) gives the full list.
9 The same unit
costs were employed whether the patient was discharged alive, or died
during the hospitalization, as the reference costs are estimated from
ﬁnished consultant episodes (FCE), which includes those discharged
alive as well as those who died during a hospitalization.
The total number of hospital admissions for each speciﬁc type of
inpatient stay is presented and compared across the treatment
groups, as is length of hospital stay. NHS Reference Costs use an
average length of stay (set nationally), that is the unit costs are per
event not per diem. As this is a multinational study that employs UK
speciﬁc costs, event costs were employed rather than per diem costs.
The unit costs for each procedure (PTCA, CABG, or cardiac trans-
plant) were used in preference to the unit cost of an associated hospi-
talization as the reference cost for a procedure includes both these
elements (the intervention and inpatient stay). Multiple procedures
(e.g. two PTCAs) were conservatively costed as a single procedure.
Concomitant medications were recorded at each study visit during
the trial. Doses were only recorded for heart failure speciﬁc medications
(e.g. loop-diuretics, thiazide diuretics, beta-blockers, ACE-inhibitors,
AT1-receptor blockers, aldosterone antagonists, and digitalis) at baseline.
The discontinuation of study medication (and compliance more gen-
erally) was checked at each follow-up visit and this information was
used to estimate the number of days on rosuvastatin. The daily cost
of 10 mg of rosuvastatin (in 2006) was £0.64.
11
Combining unit costs and resource use counts provides an estimate
of the cost of each component (CV hospitalization, procedures, medi-
cation), as well as the total cost per patient in each arm of the trial. The
difference in costs (and signiﬁcance) between the two groups was esti-
mated for all categories of cost (CV and non-CV hospitalizations and
procedures) and total cost.
Statistical and cost-effectiveness analysis
All analyses were carried out using all patients randomized using the
principle of intention-to-treat (ITT). The ITT population was deﬁned
as all patients who received a bottle of a study drug. All analyses
were performed using STATA10 (StataCorp, TX, USA).
The cost-effectiveness of statins within the trial period was estimated
by combining the estimates of cost and effect as described earlier in an
incremental cost-effectiveness ratio (ICER). The 95% conﬁdence interval
for this ratio was estimated using Fieller’s Theorem, a technique that
includes any correlation between cost and outcome.
12 Cost-
effectiveness acceptability curves (CEACs), which allow decision-makers
to assess the overall probability of a particular threshold, were also esti-
mated.
13 A CEAC shows combinations of ceiling values for the ICER and
the probabilities that the ICER falls below any given ceiling ratio based
on the observed size and variance of differences in cost and events in
the trial. All ICERs are appropriately discounted using the current dis-
count rate for the United Kingdom (3.5%) to adjust for differential
timing of costs and effects.
14 Where costs and effects are reported sep-
arately these are undiscounted (unless otherwise stated).
The cost of statin monitoring, to assess patient stability, was under-
taken as sensitivity analysis. Statin monitoring was assumed to include a
liver test
15 at the initial prescribing visits, and a further liver test and
accompanying primary care visit, valued as a GP visit,
16 6 weeks later.
Results
A total of 5011 patients were randomized in 21 countries; 2514
were assigned to receive rosuvastatin and 2497 to receive
placebo. Both groups had similar characteristics at baseline
(Table 1). The mean follow-up time was 907 days in the placebo
group and 910 days in the treatment group. The average number
of days on the study medication was 822 in the placebo group
and 839 in the rosuvastatin group (difference 17 days; 95%
CI: 23.7–38; P ¼ 0.11).
Cardiovascular hospitalizations, procedures and deaths, the
primary economic outcome measure of major CV events, and
non-CV hospitalizations are presented in Table 2. Overall, there
were signiﬁcantly fewer CV hospitalizations in the treatment
group (2191 vs. 2562; P , 0.001), and signiﬁcantly fewer hospital-
izations for any cause (CV and non-CV) (3685 vs. 4068; P ¼ 0.006).
There was no difference in the number of non-CV hospitalizations
(1494 vs. 1506). The number of other CV events including:
additional CV events occurring while in hospital; CV events not
requiring hospitalization; CV deaths; and CV procedures were
similar in the two treatment groups. When all CV events were
combined, there were signiﬁcantly fewer major CV events in the
rosuvastatin group compared with the placebo group (2613 vs.
3006; P , 0.001). The average number of major CV events per
patient was 1.20 in the placebo group, compared with 1.04 in
the intervention group (P , 0.001), such that there were 13.7%
(95% CI: 6.5–20.3%, P , 0.001) fewer major CV events in the
rosuvastatin group. When considering fatal and non-fatal major
CV events separately, there was a 2.7% (95% CI: 27.3–12.4%,
P ¼ 0.59) reduction in deaths, and 16.4% (95% CI: 8.0–23.9%,
P , 0.001) fewer non-fatal major CV events in the rosuvastatin
group.
Table 3 presents descriptive statistics for the mean length of stay
for each category of hospitalization. There was no signiﬁcant differ-
ence between the two groups.
Because the mean number of concomitant oral medications pre-
scribed during the trial was similar in the two treatment groups
[14.0 (range: 0–119) in the placebo group and 13.5 (range: 0–
103) in the rosuvastatin group; difference 0.4; 95% CI: 2 0.13–
1.01; P ¼ 0.14] these were neither valued nor included in the
estimation of total cost.
Table 4 presents the results of the cost analysis. The average cost
of CV hospitalizations for those receiving rosuvastatin was found
to be signiﬁcantly less than those receiving the placebo (£1288
vs. £1517; difference £229; 95% CI: £96–362; P ¼ 0.001). The
summation of CV hospitalization and procedure costs gave a
similar estimate; the average cost in the rosuvastatin group was
again signiﬁcantly lower (£1531 vs. £1769; difference £238; 95%
CI: £73–403; P ¼ 0.005). This equates to a 13.4% (95% CI: 4.4–
21.7%, P ¼ 0.004) reduction in CV hospitalization and procedure
costs. The cost of rosuvastatin was estimated to be £540 per
patient for the duration of the trial, therefore, the cost savings
from fewer CV hospitalizations and procedures (£238) was out-
weighed by the cost of treatment. Table 4 shows that combining
the cost of CV hospitalizations with the cost of procedures and
adding the cost of the statin resulted in a signiﬁcantly higher
average cost for those in the rosuvastatin group (£2072 vs.
£1769; difference £303; 95% CI: £138–468; P , 0.001).
A comparison of this cost with the improvement in effect (that
is an increase in the number of major CV events avoided) gave an
ICER of £1840 (95% CI: £562–6028), i.e. rosuvastatin cost £1840
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non-CV hospitalizations were included, the cost per major CV
event was slightly lower (£1759) but the conﬁdence interval was
wider (95% CI: £398–6092). When the cost of statin monitoring
was included, the cost difference increased and the ICER became
£2090 (95% CI: £729–6576) per major CV event avoided. Given
cardiac transplants are rare and expensive events and it is likely
to be chance that the placebo group had three times as many as
the rosuvastatin group (Table 3), further sensitivity analysis was
conducted that excluded these from the estimation. Table 5
shows that the exclusion of these also resulted in a slightly
higher ICER of £1987 (95% CI: £705–6230).
The extent of the uncertainty in these cost-effectiveness esti-
mates is presented in Figure 1. It is evident in each CEAC that as
the threshold increases, the curves asymptote to 1 suggesting
that there is very little uncertainty in these estimates.
Discussion
This within trial analysis of CORONA showed that the use of rosu-
vastatin in older patients with ischaemic systolic heart failure
resulted in a 14% reduction in major CV events which corresponds
to a similar reduction in associated hospitalization and procedure
costs compared to placebo. The additional cost of statin treatment,
however, resulted in signiﬁcantly higher total costs for those in the
rosuvastatin group. As such the cost savings associated with hospi-
talizations and procedures for major CV events only offset partially
the cost of rosuvastatin, so that treatment with rosuvastatin led to
an ICER of £1840 per major CV event avoided.
Although this was a multinational study, we employed UK
speciﬁc costs. A similar approach can be employed to estimate
cost-effectiveness for other countries in the trial, using country-
speciﬁc costs. However, we would expect to ﬁnd few substantial
differences because costs are merely weights for resource
use.
17,18 To control for differences in resource use between the
trial population and practice in the index country, we employed
unit costs for speciﬁc types of hospitalization and procedures,
rather than per diem costs. This meant that our analysis is less sen-
sitive to variations in length of hospital stay between countries and
that our results should be more generalizable. There was no signiﬁ-
cant difference between lengths of stay in the two treatment
groups.
Notably, this economic evaluation did not employ the trial
primary outcome, which was a time to ﬁrst event analysis, for
...............................................................................................................................................................................
Table 1 Baseline characteristics (means and proportions)
Placebo, n 5 2497 Rosuvastatin, n 5 2514 P-value
Age 72.7 72.7 0.99
Females 24 2 0.95
NYHA class 0.61
II 37 37
III 62 61
IV 1.6 1.4
Ejection fraction 0.31 0.31 0.94
BMI
a 27 27 0.53
Blood pressure
Systolic
b 129 129 0.52
Diastolic
b 76 76 0.12
Heart rate 72 72 0.61
Current smoker
c 8.3 8.9 0.41
Medical history
MI 60 60 0.87
Past or current angina 72 73 0.71
CABG 17 17 0.62
PTCA/PCI 11 12 0.66
Hypertension 63 63 0.95
Diabetes 29 30 0.90
Current atrial ﬁbrillation 23 24 0.51
Stroke 12 13 0.87
Aortic aneurysm 3.3 2.7 0.20
Intermittent claudication 13 13 0.96
Pacemaker 12 10 0.08
Implantable cardioverter-deﬁbrillator 2.6 2.9 0.51
NYHA, New York Heart Association; BMI, body mass index; MI, myocardial infarction; CABG, coronary-artery bypass grafting; PTCA, percutaneous transluminal coronary
angioplasty; PCI, percutaneous coronary intervention.
Sample size variations:
a2492, 2505;
b2497, 2513;
c2494, 2513.
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stroke. This outcome was used at the request of a regulatory auth-
ority to be in keeping with prior statin trials. It did not, however,
include the most common and expensive non-fatal outcome in
patients with heart failure, i.e. hospitalization for worsening heart
failure. For the economic evaluation of CORONA, we felt it was
...............................................................................................................................................................................
Table 2 Cardiovascular and non-cardiovascular events
Placebo n 5 2497 Rosuvastatin n 5 2514 P-value
a
Hospitalizations (number of admissions)
b
Stroke 103 86
Worsening heart failure 1298 1108 0.012
MI 142 109
Unstable angina 90 73 0.28
Non-cardiac CV 336 296
Other CV 593 519
All CV hospitalizations
i 2562 2191 ,0.001
Hospitalizations (number of patients)
Stroke 94 81
Worsening heart failure 669 622
MI 131 96
Unstable angina 71 64
Non-cardiac CV 231 226
Other CV 406 394
All CV hospitalizations 1164 1104
Additional events while in hospital (not reason for hospitalization)
ii
Stroke 10 9
Acute MI 19 28
Unstable angina 3 3
Additional events not requiring hospitalization
iii
Stroke 5 3
CV deaths
Worsening heart failure deaths 191 193 0.97
MI deaths 9 15 0.23
Sudden deaths 327 316 0.58
Other CV deaths 6 8
Non-cardiac CV deaths 60 49
Total CV deaths 593 581 0.43
CV deaths while hospitalized 186 202
CV deaths not while hospitalized
iv 407 379
Procedures
CABG 28 32
PCI 93 93
Cardiac transplant 3 1
Major CV events
c
Total number
iþiiþiiiþiv 3006 2613 ,0.001
Average number (per patient) 1.204 1.039 ,0.001
Non-CV hospitalizations (number of admissions) 1506 1494
Non-CV hospitalizations (number of patients) 840 839
All hospitalizations (number of CV and non-CV admissions) 4068 3685 0.006
All hospitalizations (number of patients)
d 1523 1489
CV, cardiovascular; MI, myocardial infarction; CABG, coronary-artery bypass grafting; PCI, percutaneous coronary intervention.
aP-values are only presented for the pre-speciﬁed trial endpoints.
bDetailed analysis of hospitalizations revealed a number of duplicate and simultaneous hospitalizations, these were investigated and corrected and as such the number of
hospitalizations reported in this table differ slightly from those reported in the clinical trial paper.
8
cMajor CV events are the summation of (i) CV hospitalizations, (ii) additional CV events while in hospital, (iii) events not requiring hospitalization, and (iv) CV deaths not while in
hospital for a CV cause.
dThe number of patients hospitalized for CV causes and non-CV causes sums to more than the number of patients hospitalized for all causes, as patients could be hospitalized for
both CV and non-CV causes during the course of the trial.
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patients, including hospitalization for worsening heart failure and
other associated CV causes, as well as CV procedures. Our ana-
lyses showed the merit of undertaking an economic evaluation of
what was a ‘non-conclusive’ clinical trial result, 8% observed rela-
tive risk reduction compared with 16% assumed relative risk
reduction.
The estimated ICER is consistent with that reported in similar
studies of statin treatment. For example, in the Heart Protection
Study (HPS), 40 mg of simvastatin once daily in a group of patients
which mainly excluded those with heart failure, the cost per major
vascular event avoided was £11600; while in a subgroup of high-
risk patients (individuals with a 42% 5 year risk of a major vascular
event) an ICER of £4500 per major vascular event avoided was
...............................................................................................................................................................................
Table 3 Length of stay (days) by type of hospitalization, mean (standard error), median (interquartile range)
Placebo Rosuvastatin P-value
Stroke 15.0 (1.4), 11 (7,18) 13.5 (1.4), 10 (5, 16) 0.47
Worsening heart failure 12.6 (0.3), 9.5 (6, 15) 11.9 (0.3), 9 (6, 15) 0.09
MI 14.8 (1.2), 11 (7, 19) 12.9 (1.0), 11 (6, 17) 0.24
Unstable angina 12.2 (1.6), 9.5 (6, 14) 13.3 (1.0), 12 (7, 18) 0.58
Non-cardiac CV 12.8 (1.0), 8 (5, 12) 13.2 (0.9), 8 (4, 15) 0.77
Other CV 8.7 (0.4), 5 (3, 10) 9.2 (0.4), 6 (3, 11) 0.37
Non CV 11.2 (0.3), 8 (4, 14) 11.2 (0.3), 8 (4, 14) 0.88
CV, cardiovascular; MI, myocardial infarction.
...............................................................................................................................................................................
Table 4 Average cost per patient (£sterling, 2005/06 prices)
Placebo (std. error) Rosuvastatin (std. error) Difference (95% CI) P-value
Cost components
Cost of CV hospitalization [a] 1517 (51) 1288 (44) 2229 (2362, 296) 0.001
Cost of procedures [b] 252 (33) 243 (27) 29( 292, 75) 0.84
Cost of non-CV hospitalizations [c] 739 (31) 726 (29) 213 (297, 70) 0.76
Cost of statin [d] - 540 (5) 540 (531, 550) ,0.001
Total costs
Total cost excluding statin costs and non-CV
hospitalization [aþb]
1769 (64) 1531 (54) 2238 (2403, 273) 0.005
Total cost excluding statin costs [aþbþc] 2508 (75) 2257 (65) 2251 (2446, 257) 0.011
Total cost excluding non-CV hospitalization [aþbþd] 1769 (64) 2072 (54) 303 (138, 468) ,0.001
Total cost [aþbþcþd] 2508 (75) 2798 (65) 289 (95, 484) 0.004
CV, cardiovascular.
...............................................................................................................................................................................
Table 5 Cost, effect, and cost-effectiveness (cost per major CV event avoided) (£sterling, 2005/06 prices)
Rosuvastatin vs. placebo Point estimate (95% CI) ICER (95% CI)
a
Incremental effect
b 0.164 (0.075, 0.254)
Incremental total cost (CV hospitalization, procedure and Tx costs) £303 (138, 467) £1840 (562, 6028)
Incremental total cost, including non-CV hospitalization £289 (95, 484) £1759 (398, 6092)
Incremental total cost, including monitoring visits £343 (179, 509) £2090 (729, 6576)
Incremental total cost, excluding cardiac transplantations £328 (176, 481) £1987 (705, 6230)
CV, cardiovascular; Tx, treatment; ICER incremental cost-effectiveness ratio.
a95% conﬁdence interval for the ICER estimated using Fieller’s Theorem.
bThis is the difference between an average of 1.204 major CV events per patient in the placebo group and 1.039 in the rosuvastatin group, see Table 2.
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19 We estimate that the baseline risk for patients in our
placebo arm was 17% per annum, nearly twice as high as the
annual risk for high-risk patients in HPS (9%), this coupled
with higher cost reduction in HPS (22% reduction in hospital
costs compared with 13%) means that the HPS ICER of £4500 is
approximately consistent with our ICER of £1840. Notably, in
the HPS lifetime analysis, statin treatment for high-risk patients
was found to be cost saving.
5
However, it is important to emphasize that the patients in HPS
were very different to those in CORONA, in that they had a much
better prognosis than the CORONA patients (as indicated by the
baseline risk) and there was also a signiﬁcant difference in the
number of fatal events in the HPS study, such that the two
outcome measures, while similar, are not directly comparable. It
is a limitation of the analysis that the composite endpoint used is
a clinical outcome measure, rather than a quality adjusted life
year (QALY) as favoured by economists. To appropriately estimate
cost per QALY would require generic health-related quality of life
data (like the EQ5D
20) which were not collected in the trial, and
also would necessitate extrapolation beyond the 3 year trial
follow-up. As survival data were collected, it would be possible
to estimate the cost per additional life year gained. However, it
would not be informative to estimate the cost per additional life
year gained since, as detailed in the trial paper,
8 there is no signiﬁ-
cant difference in survival, such that any comparison of costs and
outcomes would revert to a mere cost analysis, which would be
uninformative as it would ignore the quality of life beneﬁts of
avoiding events.
As shown in HPS, it is important to consider the role of baseline
risk and the sensitivity of cost-effectiveness estimates. Work is
ongoing in this area; however, the methodology of heterogeneity
issues is not trivial and it requires further understanding and devel-
opment. Furthermore, the model that has been developed is based
on a subsample of patients
21 (due to missing data) while our econ-
omic analysis is applicable to the sample as a whole, such that
further research is required.
In conclusion, although the primary outcome of the CORONA
study was not met, this economic analysis shows that a signiﬁcant
reduction in major CV events with rosuvastatin led to signiﬁcantly
reduced costs of CV hospitalizations and procedures. The
reduction in associated costs for major CV events was found to
offset partially (by 44%) the cost of rosuvastatin treatment in
patients with systolic heart failure.
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Appendix 2
................................................................................
Unit costs for major cardiovascular hospitalizations
and procedures (£sterling, 2005/06 values)
Resource Unit cost
Hospitalizations
Heart failure 1694
Unstable angina (ischaemic heart
disease)
1005
Acute MI 1695
Ischaemic stroke 2433
Haemorrhagic stroke 2237
Unclassiﬁable (non-transient)
stroke
2433
Arrhythmia 1072
Peripheral vascular disease 1313
Syncope or collapse 951
Other cardiac procedures 1256
Procedures
PCI 3401
CABG 8333
Cardiac transplant 32 113
Monitoring costs
Liver test 5
General practice clinic visit 31
Investigational product
Rosuvastatin (10 mg—28 day tab) 18
Sources: Department of Health
9; Healthcare Commission
15; Netten and Curtis
16;
British Medical Association and Royal Pharmaceutical Society of Great Britain
11.
CV, cardiovascular; MI, myocardial infarction; PCI, percutaneous coronary
intervention; CABG, coronary-artery bypass grafting.
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